APP
Synonyms
Amyloid intracellular domain 57, APP, Amyloid intracellular domain 59, PN-II, Amyloid-Beta A4 Protein, Beta-Amyloid Peptide, Alzheimer Disease, CTFgamma, ABETA, AAA, PN2, Amyloid beta-Peptides, Beta-CTF, Amyloid Beta Precursor Protein, Cerebral Vascular Amyloid Peptide, Beta-Amyloid Precursor Protein, Beta-Amyloid Peptide(1-40), Beta-Amyloid Peptide(1-42), Amyloid Beta A4 Protein, Alpha-secretase C-terminal fragment, AICD-50, S-APP-alpha, A4, S-APP-beta, Alzheimer disease amyloid protein, Abeta40, Gamma-CTF(59), Abeta42, Gamma-CTF(57), Alpha-CTF, Amyloid intracellular domain 50, AID(59), Gamma-CTF(50), AID(57), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, AD1, AICD-57, Beta-APP42, APPI, Beta-APP40, AID(50), CVAP, AICD-59, Amyloid Beta (A4) Precursor Protein, Peptidase Nexin-II, Protease Nexin-II, PreA4, ABPP, Testicular Tissue Protein Li 2,Description
Beta amyloid A4 protein as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis . Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity. Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapes in axons . Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu and Fe to Cu and Fe, respectively. Amyloid-beta protein 42 is a more effective reductant than amyloid-beta protein 40. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. APP42-beta may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).
KO Status
F0
Drug Information
Launched drugs: 38
Drugs in clinical trials: 9
Latest Research Phase:Approved
Drug Name
Code
Phase
Company
Indications
Clinical Trials
Florbetapir(18F)
AV-45, MNI-798
Approved
Eli Lilly And Company
Respiration Disorders, Multiple Sclerosis, Skin Diseases, Spasms, Infantile, Alzheimer Disease, Rheumatic Diseases, Parkinson Disease, Cognitive Dysfunction, Diagnostic agents, Eye Diseases, Collagen Diseases, Lewy Body Disease, Hypersensitivity, Neurodegenerative Diseases
NCT Number
NCT03333551
NCT02051790
NCT02107599
NCT01683825
NCT03040427
NCT01946243
NCT01606488
NCT01703702
NCT02164643
NCT02813434
NCT02051608
NCT00857415
NCT01400425
NCT01447719
NCT01662882
NCT02016560
NCT00857506
NCT00702143
NCT02079766
NCT00855868
NCT03430869
NCT03386669
NCT02051764
NCT03282916
NCT00857532
NCT01890343
NCT02191267
NCT01325259
NCT04588649
NCT04305210
NCT01518374
NCT04572477
NCT04309253
NCT01238458
NCT02039024
NCT02667496
NCT01254773
NCT01503944
NCT03019029
NCT01565343
NCT03019536
NCT02103894
NCT02120664
NCT03040713
NCT02062099
NCT01565330
NCT01564706
NCT01660815
NCT02167594
NCT01459016
NCT02370524
NCT02640092
NCT04474405
NCT03071224
NCT03239561
NCT03080051
NCT01565291
NCT03058965
NCT02759887
NCT02029547
NCT02488720
NCT04118764
NCT02641145
NCT01550549
NCT01565369
NCT01231971
NCT02330510
NCT02839187
NCT01565382
NCT01565356
NCT02494531
NCT02918539
NCT01746706
NCT01382849
NCT01962753
NCT03019757
NCT02266563
NCT02951598
NCT01767493
NCT02343757
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Drug
Procedure;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Procedure;Drug
Drug
Drug
Drug
Radiation;Device;Genetic
Other;Radiation
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other
Drug
Drug
Drug
Drug
Procedure;Drug
Drug
Drug
Drug
Drug
Procedure;Drug
Other
Drug
Drug
Procedure;Drug
Drug
Drug
Drug
Drug
Drug
Procedure;Other
Drug
Other;Drug;Device
Radiation;Device
Drug
Drug
Drug
Radiation
Drug
Drug
Radiation
Drug
Device
Drug
Procedure;Radiation;Genetic;Behavioral
Drug
Drug
Drug
Device
Indications
Cardiac Amyloidosis
Alzheimer's Disease
Alzheimer's Disease
Cardiac Amyloidosis
Cardiac Amyloidosis
Alzheimers Disease
Postoperative Cognitive Dysfunction
Alzheimer's Disease
Alzheimer's Disease (AD) and Related Disorders
Dementia; Cognition Disorders
Alzheimer's Disease
Alzheimer's Disease
Progressive Cognitive Decline
Alzheimer's Disease
Alzheimer's Disease; Mild Cognitive Impairment
Alzheimer's Disease
Alzheimer's Disease; Mild Cognitive Impairment
Alzheimer's Disease; Mild Cognitive Impairment
Chronic Traumatic Encephalopathy
Alzheimer's Disease
Major Depressive Disorder
Parkinsonism
Alzheimer's Disease
Alzheimer Disease; Herpes Simplex 1; Herpes Simplex 2
Parkinson's Disease
Alzheimer's Disease; Frontotemporal Dementia
Chronic Traumatic Encephalopathy
Alzheimer's Disease; Mild Cognitive Impairment
Post-stroke Dementia; Vascular Mild Cognitive Impairment
Alzheimer's Disease
Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Post-stroke Dementia, Vascular Mild Cognitive Impairment
Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia
Alzheimer's Disease
Parkinson's Disease
Dementia Alzheimer's Type
Alzheimer's Disease
Dementia With Lewy Bodies; Alzheimer's Disease; Parkinson's Disease
Amyloidosis
Alzheimer's Disease
Alzheimer Disease
Alzheimer's Disease (AD); Parkinson's Disease (PD); Chronic Traumatic Encephalopathy (CTE); Progressive Supranuclear Palsy (PSP); Frontal Temporal Dementia (FTD); Pick's Disease; Tauopathies
Alzheimer's Disease
Frontotemporal Dementia
Memory Complaint; Mild Cognitive Impairment; Alzheimer Disease
Alzheimer Disease
Alzheimer Disease
Alzheimer's Disease
Progressive Supranuclear Palsy; Corticobasal Degeneration
Alzheimer's Disease
Alzheimer's Disease (AD)
Alzheimer's Disease
Alzheimer Disease
Alzheimer Disease; Healthy Volunteers
Alzheimer Disease
Progressive Supranuclear Palsy; Alzheimer Disease; Healthy Volunteers
Alzheimer Disease
Alzheimer Disease; Healthy Volunteers; Progressive Supranuclear Palsy
Down Syndrome; Alzheimer's Dementia
Alzheimer's Disease
Cognition Disorders
Alzheimer Disease
Amyloidosis, Primary; Cardiomyopathy
Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Alzheimer's Disease
Mild Cognitive Impairment (MCI); Alzheimer's Disease (AD); Significant Memory Concern (SMC); Early Mild Cognitive Impairment (EMCI); Late Mild Cognitive Impairment (LMCI)
Alzheimer's Disease; Small Vessel Disease White Matter Hyperintensities Subtype; Vascular Cognitive Impairment
Alzheimer Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer Disease
Alzheimer Disease; Cognition Disorders
Alzheimer's Disease
Cerebral Amyloid Angiopathy
Elderly; Major Depression
Alzheimer's Disease; Lewy Body Dementia; Parkinson's Disease
Traumatic Brain Injury; Chronic Traumatic Encephalopathy; Mild Cognitive Impairment
Alzheimer Disease; Mild Cognitive Impairment
Multiple Sclerosis
Dementia; Alzheimer Disease
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
Early Phase 1
Early Phase 1
Early Phase 1
Early Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Recruiting
Completed
Completed
Recruiting
Terminated
Completed
Recruiting
Completed
Active, not recruiting
Recruiting
Active, not recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Unknown status
Terminated
Recruiting
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Recruiting
Recruiting
Unknown status
Completed
Withdrawn
Completed
Completed
Enrolling by invitation
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Withdrawn
Active, not recruiting
Recruiting
Recruiting
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Unknown status
Withdrawn
Unknown status
Recruiting
Completed
Active, not recruiting
Unknown status
Unknown status
Immune Globulin Subcutaneous (Human) (Octapharma)
Approved
Octapharma
Primary Immunodeficiency Diseases, Dermatomyositis, Immunologic Deficiency Syndromes
NCT Number
NCT02180763
NCT03939533
NCT01888484
NCT03686969
NCT02627300
NCT03907241
NCT03988426
NCT03656640
NCT04354129
NCT02111590
NCT03369301
Intervention Type
Biological
Drug
Biological
Other;Drug
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Indications
Primary Immunodeficiency (PID)
Primary Immune Deficiency Disorder
Primary Immune Deficiency Disorder
Dermatomyositis
Primary Immunodeficiency Disease
Primary Immunodeficiency
Primary Immune Deficiency Disorder
Autoimmune Diseases
Primary Immune Deficiency Disorder; Secondary Immune Deficiency
Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy; Hemolytic Anemia
Secondary Immune Deficiency
Study Phase
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
N/A
N/A
N/A
N/A
Recruitment Status
Completed
Recruiting
Completed
Terminated
Completed
Completed
Completed
Recruiting
Not yet recruiting
Completed
Recruiting
Chondroitin sulfate C lithium
Taishan Medical University Affiliated Hospital
Florapronol (18F)
18F-FC-119S, 18F-FC-119(S)
Approved
Korea Institute Of Radiological And Medical Sciences, Futurechem
Alzheimer Disease
Flutemetamol (18F)
AH-110690, GE-067
Approved
Ge Healthcare
Contrast agents, Alzheimer Disease, Cognitive Dysfunction, Hydrocephalus, Normal Pressure
NCT Number
NCT02353949
NCT02164643
NCT01672827
NCT01265394
NCT01092546
NCT01165554
NCT01028053
NCT01053312
NCT01739348
NCT03291093
NCT02423122
NCT00785759
NCT02813070
NCT03068442
NCT01202994
NCT01623284
NCT03274817
NCT01723553
NCT02120664
NCT03232632
NCT01775696
NCT00955422
NCT02781220
NCT01208675
NCT03174938
NCT02211820
NCT02778971
NCT02524405
NCT02616679
NCT02317783
NCT01303133
NCT02685969
NCT01979419
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Diagnostic Test
Drug
Other
Drug
Procedure
Indications
Mild Cognitive Impairment; Alzheimer's Disease; Dementia
Alzheimer's Disease (AD) and Related Disorders
Alzheimer's Disease; Mild Cognitive Impairment
Healthy
Normal Pressure Hydrocephalus
Brain Fibrillarab Levels
Mild Cognitive Impairment; Alzheimer's Disease
Normal Pressure Hydrocephalus
Alzheimer's Disease
Atherosclerosis
Alzheimer's Disease; Mild Cognitive Impairment
Alzheimer's Disease; Amnestic Mild Cognitive Impairment
Mild Cognitive Impairment; Alzheimer's Disease; Healthy
Cognitive Impairment; Carotid Artery Plaque; Inflammation
Alzheimer's Disease
PPA; Primary Progressive Aphasia; Aphasia; Non-fluent Aphasia; Semantic Dementia; Apraxia of Speech; Primary Progressive Nonfluent Aphasia; Progressive Aphasia
Alzheimer Disease
Atypical Alzheimers Disease; Logopenic Variant of Primary Progressive Aphasia (LPA); Posterior Cortical Atrophy (PCA)
Alzheimer's Disease
Cardiac Amyloidosis
Alzheimer's Disease
Alzheimer's Disease
Mild Cognitive Impairment; Dementia; Alzheimer's Disease
Mild Cognitive Impairment; Alzheimer's Disease; Dementia With Lewy Bodies; Vascular Dementia
Dementia; Alzheimer Disease; Parkinson Disease; Lewy Body Disease; Parkinson-Dementia Syndrome; Frontotemporal Degeneration; Semantic Dementia; Progressive Nonfluent Aphasia; Progressive Supranuclear Palsy; Corticobasal Degeneration; Multiple System Atrophy; Mild Cognitive Impairment
Brain Disease; Brain Mapping
Mild Cognitive Impairment; Dementia; Alzheimer's Disease
Alzheimer's Disease; Mild Cognitive Impairment; Vascular Cognitive Impairment; Parkinson's Disease; Lewy Body Disease
Mild Cognitive Impairment
Breast Cancer
Down Syndrome
Alzheimer's Disease
Mild Cognitive Impairment; Alzheimer's Disease; Subcortical Vascular Dementia
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Terminated
Active, not recruiting
Completed
Completed
Terminated
Completed
Completed
Completed
Terminated
Recruiting
Completed
Completed
Completed
Recruiting
Unknown status
Completed
Terminated
Completed
Completed
Terminated
Completed
Completed
Active, not recruiting
Active, not recruiting
Recruiting
Completed
Recruiting
Recruiting
Completed
Recruiting
Completed
Active, not recruiting
Active, not recruiting
Chondroitin sulfate A lithium
Taishan Medical University Affiliated Hospital
Sodium Oligomannurarate
GV-971, 971
Approved
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Ocean University Of China
Alzheimer Disease, Cognitive Dysfunction
NCT Number
NCT02293915
NCT04520412
NCT01453569
NCT03715114
NCT02986529
Intervention Type
Drug
Drug
Drug
Drug
Drug
Indications
Mild to Moderate Alzheimer Disease; Cognitive Impairment
Alzheimer Disease
Alzheimer Disease; Cognitive Impairment
Pharmacokinetics; Safety
Bioavailability
Study Phase
Phase 3
Phase 3
Phase 2
Phase 1
Phase 1
Recruitment Status
Completed
Recruiting
Completed
Recruiting
Completed
Inositol
4L6452S749
Approved
Depression, Anxiety, Diabetic Neuropathies
NCT Number
NCT03911414
NCT03757585
NCT01511835
NCT02418130
NCT01396486
NCT04306692
NCT01875445
NCT01030575
NCT00349726
NCT03864068
NCT00783705
NCT01111292
NCT00342836
NCT02081287
NCT00452829
NCT00061997
NCT01574261
NCT00012558
NCT01342874
NCT02149992
Intervention Type
Drug
Drug
Drug;Dietary Supplement
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Other;Drug
Other;Drug
Procedure
Drug
Drug
Dietary Supplement
Drug
Drug;Behavioral
Dietary Supplement
Dietary Supplement;Device
Indications
Mood Disturbance; Mood Disorders; Natural Supplements; Alternative Treatment
Non-verbal Learning Disorder; Autism Spectrum Disorder; Autism
Gestational Diabetes
Fatigue
Pediatric Bipolar Spectrum Disorders
Ovulation Induction; Polycystic Ovary Syndrome; Clomiphene; Inositol
Trichotillomania; Hair Pulling
Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Retinopathy of Prematurity; Bronchopulmonary Dysplasia (BPD)
Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Retinopathy of Prematurity; Bronchopulmonary Dysplasia (BPD)
Polycystic Ovary Syndrome; Anovulation; Hyperandrogenism; Insulin Resistance; Glucose Intolerance; Metabolic Complication
Non-small Cell Lung Cancer; Squamous Lung Dysplasia
Colon Carcinoma; Dysplasia in Crohn Disease; Low Grade Dysplasia in Ulcerative Colitis; Rectal Carcinoma
AKT
Bipolar Disorder; Manic Depression
Recurrent Neural Tube Defects
Lung Cancer; Precancerous Condition
Polycystic Ovary Syndrome
Bipolar Disorder
Gestational Diabetes Mellitus
Gestational Diabetes Mellitus as Antepartum Condition
Study Phase
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 4
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
N/A
N/A
N/A
Recruitment Status
Recruiting
Recruiting
Unknown status
Completed
Completed
Recruiting
Completed
Completed
Completed
Recruiting
Completed
Terminated
Completed
Completed
Completed
Completed
Unknown status
Completed
Completed
Unknown status
Immune globulin 10% (Grifols)
KIg-10, TAL-05-0002
Approved
Bayer Ag
Myasthenia Gravis, Primary Immunodeficiency Diseases, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Purpura, Thrombocytopenic, Idiopathic, Coronavirus Disease 2019 (COVID-19), Immunologic Deficiency Syndromes
NCT Number
NCT01465958
NCT02372149
NCT02697292
NCT03961009
NCT00376077
NCT00220740
NCT02413580
NCT02604810
NCT00220766
NCT00949065
NCT01281969
NCT04480424
NCT02690038
NCT00417573
NCT00389324
NCT02637700
NCT02915263
NCT00483119
NCT04450654
NCT00220727
NCT00090194
NCT00850005
NCT03401073
NCT02473952
NCT02473965
NCT01854827
NCT01757418
NCT03919773
NCT02042027
NCT02043379
NCT00606905
NCT00950846
Intervention Type
Biological
Drug
Drug
Biological
Drug
Drug
Biological
Biological
Drug
Biological
Drug
Biological;Drug
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Drug
Biological
Biological
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Other;Drug
Other;Biological
Procedure;Drug
Indications
Primary Immunodeficiency
Peripheral Neuropathy; Diabetes Mellitus; Chronic Inflammatory Demyelinating Polyneuropathy
Autoimmune Epilepsy
Primary Immunodeficiency Disease
Immune Thrombocytopenic Purpura
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Myasthenia Gravis Exacerbations
Primary Immunodeficiency
Immunologic Deficiency Syndrome; Agammaglobulinemia; Severe Combined Immunodeficiency; Wiskott-Aldrich Syndrome; Common Variable Immunodeficiency
Complex Regional Pain Syndrome Type 1
Obsessive-Compulsive Disorder; Children; Anxiety Disorder; Autoimmune Disease; PANDAS
COVID-19
Chronic Obstructive Pulmonary Disease
IgG Deficiency; Infections
Immunologic Deficiency Syndrome
Small Fiber Neuropathy
Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies
Pemphigus Vulgaris
Immune-Mediated Necrotizing Myopathy
Purpura, Thrombocytopenic, Idiopathic
Kidney Failure, Chronic
Neuropathic Pain
Small Fiber Neuropathy; Idiopathic Peripheral Neuropathy
Myasthenia Gravis, Generalized
Myasthenia Gravis
Biliary Atresia
Sickle Cell Disease; Pain
Postural Tachycardia Syndrome
Corneal Neovascularization; Corneal Graft Failure; Anterior Segment Inflammation
Hypogammaglobulinemia; Congenital Heart Disease
Miscarriage, Recurrent; Abortion, Habitual
Congenital Pediatric Disorders
Study Phase
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
N/A
N/A
N/A
Recruitment Status
Completed
Unknown status
Terminated
Active, not recruiting
Completed
Completed
Completed
Completed
Completed
Unknown status
Completed
Recruiting
Completed
Completed
Completed
Completed
Recruiting
Terminated
Recruiting
Completed
Terminated
Unknown status
Recruiting
Completed
Completed
Completed
Recruiting
Enrolling by invitation
Withdrawn
Completed
Completed
Active, not recruiting
TRV-101
TRV-101
Preclinical
Treventis Corp
Alzheimer Disease
BEY-2153
BEY-2153
Beyondbio Inc
YM-7555
YM-7555
Preclinical
Vitruvian Biomedical
Alzheimer Disease
Human normal immunoglobulin (Grifols)
XS-28
Approved
Grifols
Primary Immunodeficiency Diseases, Purpura, Thrombocytopenic, Idiopathic, Postpoliomyelitis Syndrome, Coronavirus Disease 2019 (COVID-19), Mucocutaneous Lymph Node Syndrome, Alzheimer Disease, Guillain-Barre Syndrome, Immunologic Deficiency Syndromes
NCT Number
NCT04566692
NCT00634569
NCT02806986
NCT03814798
NCT02176863
NCT01561053
NCT04432324
Intervention Type
Biological
Biological
Biological
Biological
Other;Biological
Biological
Biological;Drug
Indications
Primary Immunodeficiency
Primary Immune Deficiency Disease
Primary Immunodeficiency
Primary Immunodeficiency
Post-polio Syndrome
Alzheimer's Disease
COVID-19
Study Phase
Phase 4
Phase 4
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Recruitment Status
Not yet recruiting
Completed
Completed
Withdrawn
Recruiting
Completed
Recruiting
ALZ-801
ALZ-801, BLU-8499, NRM-8499
Phase 3 Clinical
Alzheon
Alzheimer Disease
NCT Number
NCT04157712
NCT04585347
Intervention Type
Drug
Drug
Indications
Alzheimer Disease
Alzheimer Disease
Study Phase
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Gantenerumab
MAb-31, R-1450, RG-1450, R-04909832
Phase 3 Clinical
Chugai Pharmaceutical Co Ltd
Alzheimer Disease
NCT Number
NCT04374253
NCT03443973
NCT02051608
NCT03444870
NCT01224106
NCT04339413
NCT04623242
NCT01760005
NCT04592341
NCT00531804
NCT01636531
NCT02133937
NCT02882009
NCT02711423
NCT03236844
NCT01656525
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Alzheimer Disease
Alzheimer Disease
Alzheimer's Disease
Alzheimer Disease
Alzheimer's Disease
Alzheimer Disease
Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Alzheimer Disease
Alzheimer's Disease
Healthy Volunteer
Healthy Volunteer
Healthy Volunteer
Healthy Volunteer
Healthy Participants
Alzheimer's Disease
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Recruitment Status
Not yet recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Completed
Recruiting
Completed
Recruiting
Recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
BAN-2401
BAN-2401
Phase 3 Clinical
Bioarctic Neuroscience
Alzheimer Disease, Cognitive Dysfunction
NCT Number
NCT03887455
NCT04468659
NCT01767311
NCT02094729
Intervention Type
Drug
Drug
Drug
Drug
Indications
Early Alzheimer's Disease
Preclinical Alzheimer's Disease; Early Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 3
Phase 3
Phase 2
Phase 1
Recruitment Status
Recruiting
Recruiting
Active, not recruiting
Completed
Aducanumab
BART, NI-10, BIIB-037
Phase 3 Clinical
Neurimmune
Alzheimer Disease, Cognitive Dysfunction
NCT Number
NCT02484547
NCT04241068
NCT02477800
NCT03639987
NCT01677572
NCT02434718
NCT01397539
NCT02782975
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Indications
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Cognitive Dysfunction; Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 3
Phase 3
Phase 3
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Recruitment Status
Terminated
Enrolling by invitation
Terminated
Terminated
Terminated
Completed
Completed
Completed
Flutafuranol F-18
AZD-4694, NAV-4694, [18F]-AZD4694, [18F]-NAV4694
Phase 3 Clinical
Astrazeneca
Alzheimer Disease, Cognitive Dysfunction, Dementia
NCT Number
NCT01886820
NCT01812213
NCT01680588
NCT00991419
NCT01325402
NCT00838877
Intervention Type
Drug
Drug
Drug
Drug
Other
Drug
Indications
Dementia; Alzheimer's Disease
Mild Cognitive Impairment
Alzheimer Disease
Alzheimer's Disease
Maximum Diagnostic Mass of [18Fluor]AZD4694
Alzheimer's Disease
Study Phase
Phase 3
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Recruitment Status
Unknown status
Unknown status
Unknown status
Completed
Completed
Completed
Solanezumab
LY-2062430
Phase 3 Clinical
Eli Lilly And Company
Alzheimer Disease, Cognition Disorders
NCT Number
NCT02008357
NCT00905372
NCT01900665
NCT00904683
NCT01127633
NCT02760602
NCT04623242
NCT01760005
NCT00749216
NCT01148498
NCT00329082
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Cognition Disorders
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Recruitment Status
Active, not recruiting
Completed
Terminated
Completed
Terminated
Terminated
Completed
Recruiting
Completed
Completed
Completed
Scyllitol
AZD-103, ELND-005
Phase 3 Clinical
Transition Therapeutics
Down Syndrome, Bipolar Disorder, Alzheimer Disease
NCT Number
NCT00568776
NCT01766336
NCT01791725
NCT01674010
NCT01735630
NCT00934050
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Alzheimer Disease
Alzheimer's Disease
Down Syndrome
Bipolar 1 Disorder
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Recruitment Status
Completed
Terminated
Completed
Terminated
Completed
Completed
[18F]THK-5117
[18F]THK-5117
Phase 2 Clinical
Tohoku University
Alzheimer Disease
[18F]THK-5105
[18F]THK-5105
Phase 2 Clinical
Tohoku University
Alzheimer Disease
Crenezumab
R-7412, RG-7412, RO-5490245, MABT-5102-A
Phase 2 Clinical
Genentech Inc, Ac Immune
Alzheimer Disease
NCT Number
NCT03114657
NCT02670083
NCT03491150
NCT01998841
NCT01397578
NCT03977584
NCT01723826
NCT01343966
NCT02427243
NCT00997919
NCT02353598
Intervention Type
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Indications
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer Disease
Alzheimer's Disease
Alzheimer's Disease
Healthy Volunteer
Healthy Volunteer
Alzheimer Disease
Study Phase
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Terminated
Terminated
Terminated
Active, not recruiting
Completed
Recruiting
Completed
Completed
Completed
Completed
Completed
Edonerpic
T-817 MA
Phase 2 Clinical
Toyama Chemical, Fujifilm Group
Stroke, Alzheimer Disease, Cognitive Dysfunction, Hepatic Insufficiency
NCT Number
NCT00663936
NCT02079909
NCT04191486
NCT02693197
Intervention Type
Drug
Drug
Drug
Drug
Indications
Alzheimer's Disease
Alzheimer's Disease
Mild Cognitive Impairment
Healthy; Hepatic Impairment
Study Phase
Phase 2
Phase 2
Phase 2
Phase 1
Recruitment Status
Completed
Completed
Recruiting
Completed
Aftobetin
ANCA-11
Phase 2 Clinical
Cognoptix Inc, University Of California San Diego
Alzheimer Disease, Cognitive Dysfunction
NCT Number
NCT02928211
Intervention Type
Radiation;Drug;Device
Indications
Mild Cognitive Impairment; Alzheimer's Disease
Study Phase
Phase 1
Recruitment Status
Unknown status
L-clausenamide
Phase 2 Clinical
Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd
Dementia, Cognitive Dysfunction, Alzheimer Disease, Memory Disorders
ABvac-40
ABvac-40
Phase 2 Clinical
Araclon Biotech
Alzheimer Disease, Cognitive Dysfunction
NCT Number
NCT03461276
NCT03113812
Intervention Type
Biological
Drug
Indications
Mild Cognitive Impairment; Alzheimer Disease
Alzheimer's Disease
Study Phase
Phase 2
Phase 1
Recruitment Status
Recruiting
Completed
Anatabine citrate
RCP-006
Phase 2 Clinical
Roskamp Institute, Rock Creek
Alzheimer Disease
NCT Number
NCT01669876
NCT01551498
NCT01428310
NCT01607619
Intervention Type
Dietary Supplement
Dietary Supplement
Dietary Supplement
Dietary Supplement
Indications
Alzheimer Disease
Thyroiditis, Autoimmune
Tobacco Use Disorder; Tobacco Dependence; Smoking
Inflammation
Study Phase
Phase 2
Phase 2
Phase 1
N/A
Recruitment Status
Terminated
Completed
Completed
Completed
Donanemab
LY-3002813, LY-3002813-IV, LY-3002813-SC
Phase 2 Clinical
Eli Lilly And Company
Brain Diseases, Alzheimer Disease, Dementia, Cognitive Dysfunction, Central Nervous System Diseases
NCT Number
NCT04437511
NCT03367403
NCT04640077
NCT02624778
NCT01837641
Intervention Type
Drug
Drug
Other;Drug
Biological;Drug
Biological;Drug
Indications
Alzheimer Disease
Alzheimer Disease
Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Cognitive Impairment
Alzheimer Disease
Alzheimer Disease
Study Phase
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Recruitment Status
Recruiting
Active, not recruiting
Recruiting
Completed
Completed
RO-7126209
RO-7126209
Phase 2 Clinical
F. Hoffmann-La Roche Ltd
Alzheimer Disease
NCT Number
NCT04639050
NCT04023994
Intervention Type
Drug
Drug
Indications
Alzheimers Disease
Alzheimers Disease
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Recruiting
Completed
CT-1812
SV-119, CT-1812
Phase 2 Clinical
Cogrx
Alzheimer Disease, Cognitive Dysfunction, Cognition Disorders
NCT Number
NCT03507790
NCT02907567
NCT03493282
NCT03716427
NCT03522129
NCT02570997
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
Alzheimer Disease
Healthy Volunteers
Alzheimer Disease
Cognitive Impairment
Study Phase
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Active, not recruiting
Completed
Active, not recruiting
Completed
Recruiting
Completed
ID-1201
ID-1201
Phase 2 Clinical
Ildong Pharmaceutical
Alzheimer Disease
NCT Number
NCT03363269
Intervention Type
Drug
Indications
Alzheimer Disease
Study Phase
Phase 2
Recruitment Status
Completed
11C-BF-227
11C-BF-227, [11C]BF-227
Phase 2 Clinical
Tohoku University
Diagnostic agents
AD-35
AD-35
Phase 2 Clinical
Zhejiang Hisun Pharmaceutical Co Ltd
Alzheimer Disease
NCT Number
NCT03790982
NCT03625401
Intervention Type
Drug
Drug
Indications
Alzheimer's Disease
Alzheimer Disease, Early Onset
Study Phase
Phase 2
Phase 2
Recruitment Status
Active, not recruiting
Active, not recruiting
APH-1105
APH-1105
Phase 2 Clinical
Aphios
Alzheimer Disease, Dementia
NCT Number
NCT03806478
Intervention Type
Other;Drug
Indications
Dementia; Alzheimer Disease 1; Alzheimer Disease 2; Alzheimer Disease 3
Study Phase
Phase 2
Recruitment Status
Not yet recruiting
Itanapraced
CHF-5074, CSP-1103
Phase 2 Clinical
Chiesi
Alzheimer Disease, Cognition Disorders
NCT Number
NCT01723670
NCT01421056
NCT01303744
NCT01602393
NCT01258452
NCT00954252
NCT01203384
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Withdrawn
Completed
Completed
Completed
Completed
Completed
Completed
KHK-6640
KHK-6640
Phase 1 Clinical
Immunas
Alzheimer Disease
NCT Number
NCT02377713
NCT02127476
NCT03093519
Intervention Type
Drug
Drug
Drug
Indications
Alzheimer's Disease
Alzheimer's Disease
Alzheimer Disease
Study Phase
Phase 1
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Completed
Indole-3-propionic acid
OX-1, IN-OX1, SHP-22, SHP-622, VP-20629
Phase 1 Clinical
Intellect Neurosciences
Friedreich Ataxia
NCT Number
NCT01898884
NCT02618343
Intervention Type
Drug
Drug
Indications
Friedreich's Ataxia
Nausea
Study Phase
Phase 1
N/A
Recruitment Status
Completed
Active, not recruiting
ASN-120290
ASN-561, ASN-120290
Phase 1 Clinical
Merck Serono
Nerve Degeneration, Alzheimer Disease
MEDI-1814
MEDI-1814
Phase 1 Clinical
Medimmune
Alzheimer Disease
NCT Number
NCT02036645
Intervention Type
Biological
Indications
Mild-Moderate Alzheimer's Disease; Healthy Elderly
Study Phase
Phase 1
Recruitment Status
Completed
Lu-AF-20513
Lu-AF-20513
Phase 1 Clinical
H. Lundbeck A/S, Otsuka
Alzheimer Disease
NCT Number
NCT03668405
NCT03819699
NCT02388152
Intervention Type
Drug
Biological;Drug
Drug
Indications
Alzheimer's Disease
Alzheimer Disease
Alzheimer Disease
Study Phase
Phase 1
Phase 1
Phase 1
Recruitment Status
Terminated
Terminated
Terminated
NPT-088
NPT-088
Phase 1 Clinical
Proclara Biosciences
Alzheimer Disease
NCT Number
NCT03008161
Intervention Type
Drug
Indications
Alzheimer Disease
Study Phase
Phase 1
Recruitment Status
Completed
A ß antibody Fab
Phase 1 Clinical
Eli Lilly And Company
Alzheimer Disease
RIV-1061-IR
RIV-1061, RIV-1061-IR
Phase 1 Clinical
Revivo Therapeutics
Alzheimer Disease, Cognition Disorders
Abeta42 antibody (Lilly)
Phase 1 Clinical
Eli Lilly And Company
Alzheimer Disease
Fol-PRI-002
Fol-PRI-002, PRI-002 prodrug
Phase 1 Clinical
Priavoid
Alzheimer Disease
PRI-002
RD-2, PRI-002
Phase 1 Clinical
Priavoid
Alzheimer Disease
NCT Number
NCT03955380
NCT03944460
Intervention Type
Drug
Drug
Indications
Alzheimer Dementia; Alzheimer Disease
Alzheimer Dementia; Alzheimer Disease
Study Phase
Phase 1
Phase 1
Recruitment Status
Completed
Completed
MRZ-99030
EG-030, GAL-101, MRZ-99030
Phase 1 Clinical
Tel Aviv University Trust
Glaucoma
NCT Number
NCT01714960
Intervention Type
Drug
Indications
Healthy Volunteers and Glaucoma Patients
Study Phase
Phase 1
Recruitment Status
Completed
123I-ABC-577
123I-ABC-577
Clinical
Nihon Medi-Physics
Diagnostic agents
Tarenflurbil spraygel (MIKA Pharma)
Clinical
Galen, Mika Pharma Gmbh
Pain, Arthritis, Rheumatoid, Skin Diseases, Inflammation, Dermatitis, Atopic
Affitope AD01
AD-1
Pending
Affiris
Alzheimer Disease
NCT Number
NCT00495417
NCT00711139
Intervention Type
Biological
Indications
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 1
N/A
Recruitment Status
Completed
Completed
Pittsburgh Compound B
[11C]PIB, [11C]6-OH-BTA-1, 11C-PIB
Pending
The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet
Contrast agents
NCT Number
NCT00950430
NCT03969732
NCT04134923
NCT03555292
NCT03981380
NCT03503331
NCT03958630
NCT04364672
NCT04542603
NCT01826110
NCT03757910
NCT03746366
NCT04263337
NCT04579120
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Radiation;Drug
Drug
Drug
Indications
Alzheimer's Disease; Dementia With Lewy Bodies; Frontotemporal Dementia; Vascular Dementia
Cerebral Amyloid Angiopathy; Intracranial Hemorrhages; Alzheimer Disease
Alzheimer Disease
Parkinson Disease
Cognitive Impairment; Vascular Diseases; Alzheimer Disease; Atherosclerosis
Alzheimer Disease
Dementia
Breast Cancer
Ovarian Cancer
Alzheimer's Disease
Alzheimer Disease
Alcohol Use Disorder
Concussion, Brain
Alzheimer Disease
Study Phase
Phase 4
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
Early Phase 1
N/A
N/A
Recruitment Status
Enrolling by invitation
Recruiting
Active, not recruiting
Recruiting
Enrolling by invitation
Recruiting
Recruiting
Not yet recruiting
Not yet recruiting
Completed
Enrolling by invitation
Completed
Enrolling by invitation
Not yet recruiting
18F-FDDNP
Pending
Siemens Medical Solution, University Of California At Los Angeles
Brain Injuries, Traumatic, Alzheimer Disease, Diagnostic agents
NCT Number
NCT02214862
NCT04311281
NCT02003183
Intervention Type
Drug
Biological
Radiation
Indications
Progressive Supranuclear Palsy; Multi-System Atrophy; Parkinsonism
Suspected Chronic Traumatic Encephalopathy (CTE) or Traumatic Encephalopathy Syndrome (TES); Suspected Alzheimer's Disease (AD)
CTE; TBI (Traumatic Brain Injury)
Study Phase
Early Phase 1
N/A
N/A
Recruitment Status
Completed
Not yet recruiting
Completed
Alzheimer's Disease Vaccine (Mercia Pharma)
MER-5101
Pending
Mercia Pharma
Alzheimer Disease
VM-100
VM-100
Pending
Vision Medicines
Macular Degeneration
sGC-1061
sGC-1061
Pending
Sgc Pharma
Alzheimer Disease
SAN-61
SAN-61, SAN-161
Pending
Diamedica
Alzheimer Disease
PTI-80
PTI-80
Pending
Proteotech
Alzheimer Disease
GRL-8234
Pending
University Of Illinois, Oklahoma Medical Research Foundation, Comentis, Purdue Research Foundation
Alzheimer Disease
BGC-1178
RS-1178, BGC-1178, BGC-20-1178
Pending
Daiichi Sankyo Co Ltd
Alzheimer Disease
RQ-9
RQ-9, AAT-009, RQ-00000009
Pending
Raqualia Pharma
Alzheimer Disease
AZP-2006
AZP-2006
Pending
Alzprotect
Supranuclear Palsy, Progressive, Alzheimer Disease
DWP-09031
DWJ-302, DWP-09031
Pending
Daewoong Pharmaceutical Co Ltd
Alzheimer Disease
NCT Number
NCT01522586
Intervention Type
Drug
Indications
Healthy
Study Phase
Phase 1
Recruitment Status
Terminated
Heparin-derived oligosaccharide-C3
HDO-C3, HF-0420
Pending
Loyola University Chicago
Peripheral Nervous System Diseases
18F-MNI-558
18F-MNI-558
Pending
Invicro, Molecular Neuroimaging
Alzheimer Disease
NCT Number
NCT01217021
Intervention Type
Drug
Indications
Alzheimer Disease
Study Phase
Early Phase 1
Recruitment Status
Completed
RS-0466
RS-0466, BGC-200466, BGC-20-0466
Pending
Daiichi Sankyo Co Ltd
Alzheimer Disease
E-2212
GSM-2, GSM-A, E-2212
Pending
Eisai Co Ltd
Alzheimer Disease
NCT Number
NCT01221259
Intervention Type
Drug
Indications
Alzheimer's Disease
Study Phase
Phase 1
Recruitment Status
Completed
CNDR-51526
Pending
University Of Pennsylvania
Alzheimer Disease
RS-0406
RS-0406, BGC-200406, BGC-20-0406
Pending
Daiichi Sankyo Co Ltd
Alzheimer Disease
ABvac-42
ABvac-42
Pending
Araclon Biotech
Alzheimer Disease
Bapineuzumab
h3D6, AAB-001, PF-5236801, AAB-001 SubQ
Discontinued
Pfizer Inc, Elan Corp
Alzheimer Disease
NCT Number
NCT00574132
NCT00676143
NCT00575055
NCT00937352
NCT00667810
NCT00996918
NCT00998764
NCT00663026
NCT00112073
NCT00606476
NCT00916617
NCT00174525
NCT01254773
NCT00397891
NCT01658722
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Alzheimer's Disease
Alzheimer Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer Disease
Alzheimer Disease
Alzheimer Disease
Alzheimer Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer Disease
Alzheimer's Disease
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
N/A
Recruitment Status
Completed
Terminated
Completed
Terminated
Terminated
Terminated
Terminated
Completed
Completed
Terminated
Terminated
Unknown status
Completed
Completed
Terminated
Dehydroevodiamine hydrochloride
DHED, JES-9501
Discontinued
Jeil Pharmaceutical, University Of Seoul
Alzheimer Disease
AAB-003
AAB-003, PF-5236812, PF-05236812
Discontinued
Pfizer Pharmaceuticals Ltd (China), Elan Corp
Alzheimer Disease
NCT Number
NCT01369225
NCT01193608
Intervention Type
Drug
Other;Drug
Indications
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 1
Phase 1
Recruitment Status
Completed
Completed
CAD-106
CAD-106
Discontinued
Kuros Biosciences, Novartis Pharma Ag
Alzheimer Disease
NCT Number
NCT02565511
Intervention Type
Other;Biological;Drug
Indications
Alzheimer's Disease
Study Phase
Phase 2/Phase 3
Recruitment Status
Terminated
NP-0361
NP-61, NP 0361
Discontinued
Noscira
Alzheimer Disease
AD-04 (AFFiRiS)
AD-04-AFFiRiS
Discontinued
Affiris
Alzheimer Disease
Vanutide cridificar
AAC-001, ACC-001, CRM-197, PF-5236806, PF-05236806
Discontinued
Elan Pharma International, Janssen Global Services Llc, Pfizer Inc
Alzheimer Disease
NCT Number
NCT01238991
NCT00752232
NCT00960531
NCT00959192
NCT01284387
NCT00955409
NCT00498602
NCT00479557
NCT01227564
NCT02223637
Intervention Type
Biological
Other;Biological
Biological
Other;Biological
Biological
Drug
Other;Biological
Biological;Drug
Other;Biological
Biological
Indications
Alzheimer's Disease
Alzheimer Disease
Alzheimer Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer Disease
Alzheimer Disease
Alzheimer Disease
Alzheimer's Disease
Meningococcal Disease; Pregnancy; Infections, Meningococcal
Study Phase
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
N/A
Recruitment Status
Terminated
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Affitope-AD03
AD-03, Affitope-AD03
Discontinued
Affiris
Alzheimer Disease
NCT Number
NCT01309763
NCT01568086
Intervention Type
Biological
Indications
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 1
N/A
Recruitment Status
Completed
Terminated
Birtamimab
NEOD-001
Discontinued
Prothena
Immunoglobulin Light-chain Amyloidosis
NCT Number
NCT02312206
NCT02613182
NCT02632786
NCT03154047
NCT03168906
NCT01707264
Intervention Type
Other;Drug
Drug
Drug
Drug
Drug
Drug
Indications
Primary Systemic (AL) Amyloidosis
AL Amyloidosis
AL Amyloidosis
AL Amyloidosis
Amyloidosis
Primary Amyloidosis
Study Phase
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Recruitment Status
Terminated
Terminated
Completed
Terminated
Terminated
Completed
UBITh AD immunotherapeutic vaccine (United Biomedical)
UB-311
Discontinued
United Biomedical
Alzheimer Disease
NCT Number
NCT03531710
NCT02551809
NCT00965588
Intervention Type
Biological;Drug
Biological;Drug
Biological
Indications
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 2
Phase 2
Phase 1
Recruitment Status
Terminated
Completed
Completed
SAR-228810
SAR-228810
Discontinued
Sanofi
Alzheimer Disease
NCT Number
NCT01485302
Intervention Type
Drug
Indications
Alzheimer's Disease
Study Phase
Phase 1
Recruitment Status
Completed
Ab40-4-42
Ab40-4-42
Discontinued
Ilsung Pharmaceutical
Alzheimer Disease
PF-04382923
RN-6G, PF-4382923, PF-04382923
Discontinued
Pfizer Pharmaceuticals Ltd (China)
Macular Degeneration
NCT Number
NCT01577381
Intervention Type
Biological
Indications
Age-Related Maculopathy
Study Phase
Phase 2
Recruitment Status
Terminated
Ponezumab
RI-1219, RN-1219, PF-4360365, PF-04360365
Discontinued
Pfizer Pharmaceuticals Ltd (China)
Cerebral Amyloid Angiopathy, Alzheimer Disease
NCT Number
NCT00722046
NCT00945672
NCT01821118
NCT00607308
NCT00733642
NCT01005862
NCT01125631
NCT00455000
Intervention Type
Biological;Drug
Biological;Drug
Other;Biological
Biological;Drug
Biological
Biological;Drug
Biological;Drug
Biological;Drug
Indications
Alzheimer's Disease
Alzheimer's Disease
Cerebral Amyloid Angiopathy
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Alzheimer disease vaccine (Elan)
AIP-001, AN-1792
Discontinued
Elan Pharmaceuticals
Alzheimer Disease
NCT Number
NCT00021723
Intervention Type
Biological
Indications
Alzheimer's Disease
Study Phase
Phase 2
Recruitment Status
Terminated
11C-6-Me-BTA-1
11C-BTA-1, 11C-6-Me-BTA-1, carbon-11-6-Me-BTA-1
Discontinued
University Of Pittsburgh
Alzheimer Disease
[123I]MNI-168
MNI-168
Discontinued
Inst For Neurodegenerative Disorders
Diagnostic agents
NCT Number
NCT00870519
Intervention Type
Drug
Indications
Alzheimer's Disease
Study Phase
Phase 1
Recruitment Status
Terminated
M-266
M-266
Discontinued
Eli Lilly And Company, Washington University School Of Medicine
Alzheimer Disease
GSK-933776
GSK-933776, GSK-933776A
Discontinued
Glaxosmithkline Plc
Alzheimer Disease, Geographic Atrophy, Macular Degeneration
NCT Number
NCT01342926
NCT02033668
NCT01424436
NCT00459550
Intervention Type
Drug
Drug
Biological
Drug
Indications
Atrophy, Geographic
Atrophy, Geographic
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Completed
Completed
Tramiprosate
3-APS, NC-531, NC-758
Discontinued
Bellus Health
Stroke, Alzheimer Disease
NCT Number
NCT00088673
NCT00314912
NCT00217763
NCT00056238
NCT03382353
Intervention Type
Drug
Drug
Drug
Drug
Dietary Supplement;Behavioral
Indications
Alzheimer Disease
Alzheimer's Disease
Alzheimer's Disease
Stroke; Neurologic Diseases, General
Lifestyle Risk Reduction
Study Phase
Phase 3
Phase 3
Phase 3
Phase 2
N/A
Recruitment Status
Unknown status
Unknown status
Unknown status
Completed
Unknown status
PPI-1019
PPI-1019
Discontinued
Glaxosmithkline Plc
Alzheimer Disease
NCT Number
NCT00100334
NCT00100282
Intervention Type
Drug
Drug
Indications
Alzheimer's Disease
Alzheimer's Disease
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Completed
Completed